Proposed Data Collection Submitted for Public Comment and Recommendations, 13927-13928 [2019-06815]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 67 / Monday, April 8, 2019 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–06813 Filed 4–5–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–19–0009; Docket No. CDC–2019–
0014]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled ‘‘National Disease Surveillance
Program—I. Case Reports’’ to collect
disease-specific surveillance reports of
four rare, uncommon, or infrequent
diseases.
SUMMARY:
CDC must receive written
comments on or before June 7, 2019.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0014 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
jbell on DSK30RV082PROD with NOTICES
DATES:
Please note: Submit all comments through
the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
To request
more information on the proposed
project or to obtain a copy of the
information collection plan and
FOR FURTHER INFORMATION:
VerDate Sep<11>2014
17:45 Apr 05, 2019
Jkt 247001
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
National Disease Surveillance
Program—I. Case Reports—Revision—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Surveillance of the incidence and
distribution of disease has been an
important function of the US Public
Health Service (PHS) since an 1878 Act
of Congress authorized the PHS to
collect morbidity reports. After the
Malaria Control in War Areas Program
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
13927
had fulfilled its original 1942 objective
of reducing malaria transmission, its
basic tenets were carried forward and
broadened by the formation of the
Communicable Disease Center (CDC) in
1946. CDC was conceived of as a wellequipped, broadly staffed agency used
to translate facts about analysis of
morbidity and mortality statistics on
communicable diseases and through
field investigations.
It was soon recognized that control
measures (such as the DDT spraying for
malaria) did not alleviate the threat of
disease reintroduction. In 1950, the
Malaria Surveillance Program began and
in 1952, the National Surveillance
Program started. Both programs were
based on the premise that diseases
cannot be diagnosed, prevented, or
controlled until existing knowledge is
expanded and new ideas developed and
implemented. The original scope of the
National Surveillance Program included
the study of malaria, murine typhus,
smallpox, psittacosis, diphtheria,
leprosy, and sylvatic plague. Over the
years, the mandate of CDC has
broadened in preventive health
activities and the surveillance systems
maintained have expanded. This
program is authorized under the Public
Health Service Act, Section 301 and 306
(42 U.S.C. 241 and 242K).
This ICR covers surveillance activities
for these four, rare diseases:
1. Creutzfeldt-Jakob Disease (CJD)
2. Reye Syndrome
3. Kawasaki syndrome
4. Acute Flaccid Myelitis
Changes are being requested only to
the Kawasaki Syndrome form. The CDC
KD form has been used as part of a
passive national surveillance system to
collect additional case information,
including data on cardiac complications
and treatment. In recent years, new
treatments and/or treatment
combinations have been implemented at
some institutions; this information is
not collected on the current form. Also,
more specific information regarding the
results of coronary artery testing would
be beneficial for assessing disease
severity and treatment effectiveness. To
incorporate these additions to the form
without increasing the estimated
burden, some current questions on the
form, specifically those collecting
information on the presence or absence
of certain complications, will be
removed. The form will be targeted to
sentinel KD research centers across the
US, reducing the number of respondents
compared to previous years.
Annual burden is estimated to
decrease by 53 hours since the last
approval (June, 2019). There is no cost
E:\FR\FM\08APN1.SGM
08APN1
13928
Federal Register / Vol. 84, No. 67 / Monday, April 8, 2019 / Notices
to respondents other than the time to
participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Total burden
(in hours)
Form name
Epidemiologists .................................
CJD ..................................................
Kawasaki Syndrome ........................
Reye Syndrome ...............................
Acute Flaccid Myelitis ......................
10
25
50
100
2
10
1
1
20/60
15/60
20/60
30/60
7
63
17
50
Total ...........................................
...........................................................
........................
........................
........................
137
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–06815 Filed 4–5–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2019–0029; NIOSH–327]
Mesothelioma Registry Feasibility;
Request for Information
Centers for Disease Control and
Prevention, HHS.
ACTION: Request for information.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH), within the Centers for Disease
Control and Prevention (CDC),
announces the opening of a docket to
obtain information on the feasibility of
a registry designed to track
mesothelioma cases in the United
States, as well as recommendations on
enrollment, data collection,
confidentiality, and registry
maintenance. The purpose of such a
registry would be to collect information
that could be used to develop and
improve standards of care and to
identify gaps in mesothelioma
prevention and treatment.
DATES: Comments must be received by
July 8, 2019.
ADDRESSES: Comments may be
submitted electronically, through the
Federal eRulemaking Portal: https://
www.regulations.gov, or by sending a
hard copy to the NIOSH Docket Office,
Robert A. Taft Laboratories, MS–C34,
1090 Tusculum Avenue, Cincinnati, OH
45226. All written submissions received
must include the agency name (Centers
for Disease Control and Prevention,
HHS) and docket number (CDC–2019–
SUMMARY:
jbell on DSK30RV082PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondents
VerDate Sep<11>2014
17:45 Apr 05, 2019
Jkt 247001
0029; NIOSH–327) for this action. All
relevant comments, including any
personal information provided, will be
posted without change to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Rachel Weiss, Program Analyst, 1090
Tusculum Avenue, MS: C–48,
Cincinnati, OH 45226; telephone (855)
818–1629 (this is a toll-free number);
email NIOSHregs@cdc.gov.
SUPPLEMENTARY INFORMATION: The fiscal
year 2019 appropriations act charged
NIOSH with initiating a feasibility study
for a National Mesothelioma Registry.1
Mesothelioma is a rare cancer of the
body’s lining tissue, most commonly the
lining of the chest and lungs (pleura)
and the lining of the abdomen
(peritoneum). The most common risk
factor for mesothelioma is prior asbestos
exposure. Mesothelioma treatments are
limited and survival is generally poor.
NIOSH is the Federal agency that
develops new knowledge in the field of
occupational safety and health and
transfers that knowledge into practice.
NIOSH has a strong interest in
preventing mesothelioma and helping
people with the disease, since the most
common known cause is exposure to
asbestos, a dangerous occupational
hazard for many workers.
Cancer is a reportable disease in every
state. Data about new cases of
mesothelioma are reported to state or
local cancer registries, annually
submitted to CDC or the National
Cancer Institute (NCI), and then
compiled by CDC in the U.S. Cancer
1 Department of Defense and Labor, Health and
Human Services, and Education Appropriations
Act, 2019 and Continuing Appropriations Act,
2019, HR 6157 (enacted). See also Department Of
Defense for the Fiscal Year Ending September 30,
2019, and for Other Purposes, House of
Representatives Conference Report No. 115–952
(2018). The conference report accompanies HR 6157
and explicitly directs NIOSH to ‘‘initiate a
feasibility study for a patient registry, which would
include developing case finding methodology to
determine incidence and prevalence, demographics,
and risk factors.’’
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Statistics database.2 However, existing
cancer registries collect only limited
information about potential risk factors
and issues occurring over time, such as
treatment complications. In addition to
the limitations on the scope of existing
surveillance systems, it may take 6
months or more from the time of
diagnosis until mesothelioma cases are
initially reported to a cancer registry,
and then another 1–2 years to be
reported in U.S. Cancer Statistics.
Because about half of those diagnosed
with mesothelioma die within 1 year, to
be of benefit to registrants, a registry
would need to develop a case-finding
methodology to enroll registrants as
soon as possible after diagnosis to allow
timely access to contemporary state-ofthe-art therapy and clinical trials. It has
been reported that many mesothelioma
patients do not receive this level of
care.3 Ideally, the case-finding
methodology would be national in
scope and identify most people
diagnosed with mesothelioma, thus
allowing researchers to use this current
data to determine incidence and
prevalence, demographics, and risk
factors, as required by the 2019
appropriations act. A National
Mesothelioma Registry could address
the limitations of existing registries by
reducing case reporting delays,
collecting detailed information
regarding risk and prognostic factors,
and by engaging with researchers to
better enable them to identify gaps in
the current understanding of
mesothelioma prevention and treatment
and improve the standard of care for
current and future patients.
In order to study the feasibility of
establishing a National Mesothelioma
Registry, NIOSH requests information
2 U.S. Cancer Statistics: the Official Federal
Cancer Statistics. https://www.cdc.gov/cancer/uscs/
index.htm.
3 Waller DA [2018], The Management of
Malignant Pleural Mesothelioma in the USA 2004–
13—A Decade of Lost Opportunity? J Thorac Dis
10(Suppl 9):S1044–S1046.
E:\FR\FM\08APN1.SGM
08APN1
]]>Agencies
[Federal Register Volume 84, Number 67 (Monday, April 8, 2019)]
[Notices]
[Pages 13927-13928]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06815]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-19-0009; Docket No. CDC-2019-0014]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled ``National Disease Surveillance
Program--I. Case Reports'' to collect disease-specific surveillance
reports of four rare, uncommon, or infrequent diseases.
DATES: CDC must receive written comments on or before June 7, 2019.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0014 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal
eRulemaking portal (regulations.gov) or by U.S. mail to the address
listed above.
FOR FURTHER INFORMATION: To request more information on the proposed
project or to obtain a copy of the information collection plan and
instruments, contact Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
National Disease Surveillance Program--I. Case Reports--Revision--
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Surveillance of the incidence and distribution of disease has been
an important function of the US Public Health Service (PHS) since an
1878 Act of Congress authorized the PHS to collect morbidity reports.
After the Malaria Control in War Areas Program had fulfilled its
original 1942 objective of reducing malaria transmission, its basic
tenets were carried forward and broadened by the formation of the
Communicable Disease Center (CDC) in 1946. CDC was conceived of as a
well-equipped, broadly staffed agency used to translate facts about
analysis of morbidity and mortality statistics on communicable diseases
and through field investigations.
It was soon recognized that control measures (such as the DDT
spraying for malaria) did not alleviate the threat of disease
reintroduction. In 1950, the Malaria Surveillance Program began and in
1952, the National Surveillance Program started. Both programs were
based on the premise that diseases cannot be diagnosed, prevented, or
controlled until existing knowledge is expanded and new ideas developed
and implemented. The original scope of the National Surveillance
Program included the study of malaria, murine typhus, smallpox,
psittacosis, diphtheria, leprosy, and sylvatic plague. Over the years,
the mandate of CDC has broadened in preventive health activities and
the surveillance systems maintained have expanded. This program is
authorized under the Public Health Service Act, Section 301 and 306 (42
U.S.C. 241 and 242K).
This ICR covers surveillance activities for these four, rare
diseases:
1. Creutzfeldt-Jakob Disease (CJD)
2. Reye Syndrome
3. Kawasaki syndrome
4. Acute Flaccid Myelitis
Changes are being requested only to the Kawasaki Syndrome form. The
CDC KD form has been used as part of a passive national surveillance
system to collect additional case information, including data on
cardiac complications and treatment. In recent years, new treatments
and/or treatment combinations have been implemented at some
institutions; this information is not collected on the current form.
Also, more specific information regarding the results of coronary
artery testing would be beneficial for assessing disease severity and
treatment effectiveness. To incorporate these additions to the form
without increasing the estimated burden, some current questions on the
form, specifically those collecting information on the presence or
absence of certain complications, will be removed. The form will be
targeted to sentinel KD research centers across the US, reducing the
number of respondents compared to previous years.
Annual burden is estimated to decrease by 53 hours since the last
approval (June, 2019). There is no cost
[[Page 13928]]
to respondents other than the time to participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Epidemiologists............... CJD............. 10 2 20/60 7
Kawasaki 25 10 15/60 63
Syndrome.
Reye Syndrome... 50 1 20/60 17
Acute Flaccid 100 1 30/60 50
Myelitis.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 137
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2019-06815 Filed 4-5-19; 8:45 am]
BILLING CODE 4163-18-P
